245 The role of the MR 7 Supplemental Table 4. Continued Hazard ratio 95%-CI Lower bound Upper bound Cytogenetic subtype1 ETV6-RUNX1 Other 2.45 0.57 10.51 CNS involvement2 No Yes 7.73 1.70 35.15 Unknown 0.62 0.14 2.81 Leucocytes at diagnosis <10 10-25 1.38 0.52 3.66 25-50 0.73 0.15 3.58 50-100 1.51 0.32 7.20 >100 1.91 0.51 7.17 NCI risk group NCI standard risk NCI high risk 1.33 0.58 3.03 Prednisone response day 83 Good Poor 2.34 0.66 8.25 Risk group stratification4 SR MR 2.10 0.59 7.54 HR 10.33 2.19 48.71 MRD day 335 Negative Positive 2.59 0.74 9.06 MRD day 796 Negative Positive 4.22 1.57 11.28 GR (NR3C1) expression Low High 0.96 0.40 2.30 MR (NR3C2) expression Low High 0.57 0.24 1.33 Hazard ratio is depicted for the first occurring event. NCI-risk category: standard risk= <10 years and white cell count at diagnosis <50x109/L, high risk= other. 1 Groups too small: only 2 events in ETV6-RUNX1 group 2 Groups too small: only 2 events in group with CNS involvement 3 Landmark analysis, starting at day 8: 1 event (induction failure) lost 4 Groups too small: only 3 events in the standard risk group 5 Landmark analysis, starting at day 33: 1 event (induction failure) lost 6 Landmark analysis, starting at day 79: 1 event (induction failure) lost Abbreviations: CI: confidence interval, ALL: acute lymphoblastic leukemia, CNS: central nervous system, NCI: National Cancer Institute, SR: standard risk, MR: medium risk, HR: high risk, MRD: minimal residual disease, GR: glucocorticoid receptor, MR: mineralocorticoid receptor
RkJQdWJsaXNoZXIy MTk4NDMw